Announcing our Investment in Science&Humans
We are thrilled to announce our investment in Science&Humans, a company building an integrated platform for hormone health through at-home diagnostics, virtual clinical consults and vertically integrated pharmacy experience. The investment comes as part of a Series A financing that we led with participation from WELL health, Michele Romanow and a group of US-based family offices and clinicians.
Introducing Science&Humans
Science&Humans was founded by Aftab Pashaw and Hira Siddiqui to make clinically rigorous, continuous and accessible hormone care. The team has built a full‑stack experience that connects testing, nurse practitioner-led care plans and convenient medication management in one place. Clinical programs address key needs across perimenopause and menopause, testosterone therapy for men and metabolic health.
The company serves patients directly with a consumer offering, while also building a growing enterprise channel with insurers, employers and other benefit sponsors. The operating model focuses on safety, consistency and measurable outcomes, supported by product and clinical expertise.
Closing a Critical Gap in Care
Hormone health is foundation to quality of life, yet the experience for patients is too often defined by waitlists, fragmented pathways and inconsistent protocols and limited diagnostic access. This results in delayed intervention and reactive care.
Science&Humans is built for preventive care and longevity, tackles this gap with an integrated model that links testing, treatment and follow-up, supported by technology that enables consistent, personalized care.
Why We Invested
At Pender Ventures, we start with the team. The leaders behind Science&Humans are mission driven, committed and passionate about the problem they are solving, with complementary strengths across product, clinical operations and GTM. The company was bootstrapped prior to this institutional round and has operated with discipline and capital efficiency, while keeping patient outcomes at the centre.
As the field moves past blanket conclusions from older literature, demand for evidence-based, individualized hormone care is accelerating. This is a large, underpenetrated market, hormone health is the wedge, and the platform opportunity is just getting started.
We also believe the company is positioned to scale and that hormone health is the starting point, not the endpoint. With vertical integration across at-home diagnostics and pharmacy, Science&Humans controls more of the care pathway. This vertical integration creates a foundation to expand into adjacent areas over time. Early consumer traction and a growing enterprise channel through employers and insurers provide a durable foundation for long-term growth.
Looking Ahead
We are excited to partner with Science&Humans as they expand access to hormone care, deepen clinical programs and build the infrastructure required to deliver high quality, continuous care at scale. If you see an angle for collaboration, please reach out.
Back to top ↖